Maria V. Davydovskaya

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.

Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.

Journal: Neurology and therapy

Published: May 03, 2022

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.

Journal: Neurology and therapy

Published: January 26, 2022

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: October 04, 2021

Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis

Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: September 05, 2021

Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in the Russian Population.

Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in the Russian Population.

Journal: Journal of the International Neuropsychological Society : JINS

Published: June 16, 2021

Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis

Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: September 15, 2020

Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)

Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: April 24, 2020

The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis

The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: January 15, 2020

Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.

Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.

Journal: PloS one

Published: December 03, 2018

The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy

The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: January 24, 2018

Drug Policy in the Russian Federation.

Drug Policy in the Russian Federation.

Journal: Value in health regional issues

Published: December 31, 2017

Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis

Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: March 03, 2017

Showing 1-12 of 18

Last Updated: 09/26/2026